Immunomedics, Inc. (IMMU) News
Filter IMMU News Items
IMMU News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest IMMU News From Around the Web
Below are the latest news stories about Immunomedics Inc that investors may wish to consider to help them evaluate IMMU as an investment opportunity.
The Company announces that, after careful consideration, Harout Semerjian has decided to step down from his role as President and Chief Executive Officer (CEO) of Immunomedics. Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward. Patient enrollment into the Phase 3 TROPiCS-02 study of Trodelvy in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, has been resumed at approximately 20 clinical sites as of mid-May, with additional sites continuing to open in the coming weeks.
Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.
Is (IMMU) Outperforming Other Medical Stocks This Year?
Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.
Trodelvy™ received accelerated approval from FDA for third-line metastatic triple-negative breast cancer First patient treated with Trodelvy following…
Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Daily Biotech Pulse: FDA Nod For Immunomedics, Lilly's Solid Q1 Beat, Predictive Oncology Restructures Debt
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks htitting 52-week highs April 22.) …
Thinking about buying stock in Chesapeake Energy Corp, General Electric, Immunomedics, TOP Ships, or United Airlines?
NEW YORK, April 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CHK, GE, IMMU, TOPS, and UAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
The company won an early FDA approval yesterday for its drug to treat advanced breast cancer.
Immunomedics Inc on Wednesday won the U.S. Food and Drug Administration approval for its therapy for a form of breast cancer that has worsened despite two prior rounds of treatment, according to the therapy's label from the agency.